上海醫藥(02607.HK)旗下製劑臨牀試驗申請獲內地受理
上海醫藥(02607.HK)公佈,全資子公司上海上藥信誼藥廠WST04製劑(膠囊)的臨牀試驗申請,獲得國家藥品監督管理局受理。
WST04製劑是一種口服微生態活菌製劑,擬用於治療晚期惡性實體瘤。臨牀前研究顯示WST04製劑可顯着增強免疫檢查點抑制劑的抗腫瘤作用。
該項目由上藥信誼自主研發,並擁有完全知識產權。目前全球尚無同類微生態活菌藥物上市。該項目已累計投入研發費用約589.53萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.